Replies to post #3051 on Imprimis Pharmaceuticals Inc (IMMY)

[ronk]

I think it's going to look great next to Q3 2014.

IMMY is so new, the execution of their business plan really began in 2014. In 2015 they began acquiring pharmacies to launch their proprietary treatments and it sounds like their dropless eye therapy is really the clean up hitter for them.

2015 you can see real growth in their numbers - quarter to quarter - but they did acquire 3 pharmacies in September. Acquisitions could reflect negatively on a report but that's ok.

They forecasted better earnings for their urology treatment and stated their sales goals are about 60 days behind. That's why I think Q4, Q1 2016 are going to be really good.

Then the 2 new 503B compounding pharmacies will be reflected in Q2 2016 reports, barring any setbacks, I believe.